Celltrio Secures $15M to Accelerate Global Expansion in Cell Therapy Automation

Celltrio Secures $15 Million Investment
FREMONT, Calif.–Celltrio®, a leader in life sciences automation, has successfully closed a $15 million financial investment round. The funding was led by Premier Partners, a top investor in healthcare innovation. This significant investment highlights the trust in Celltrio’s mission to advance cell culturing and cell & gene therapy through cutting-edge automation.
Introducing RoboCell®: Revolutionizing Cell Culturing
Celltrio’s flagship product, RoboCell®, is a modular platform designed for fully automated and sterile cell culturing and cell therapy manufacturing. This innovative system streamlines complex processes, ensuring high-throughput and consistent results. RoboCell® is set to transform biopharma, regenerative medicine, and advanced research laboratories by enhancing efficiency and reliability.
Strategic Use of Funds to Drive Growth
The newly acquired funds will accelerate the global commercialization of RoboCell®. Celltrio plans to scale its manufacturing capabilities to meet increasing demand. Additionally, the investment will support the expansion of commercial operations across North America, Europe, and Asia. This financial boost will also fuel ongoing innovation, ensuring Celltrio remains at the forefront of GMP-ready automation solutions.
Leadership Shares Vision for the Future
Charlie Duncheon, CEO of Celltrio, expressed excitement about the investment, stating it marks a major milestone for the company. He emphasized the partnership with Premier Partners as a shared vision to transform cell-based therapies through advanced automation. Jay Song, CEO of Premier Partners, praised Celltrio’s strong customer traction and unique intellectual property, positioning the company as a future leader in automated cell culturing solutions.
About Celltrio®
Celltrio designs and manufactures scalable cell culture automation platforms that integrate seamlessly into both R&D and GMP environments. Their RoboCell® system automates sterile cell culturing and cell and gene therapy processes, delivering high-throughput and consistent results. By serving biopharma, cell therapy, and regenerative medicine laboratories, Celltrio is advancing the field of life sciences automation. More information can be found at www.celltrio.com.
Conclusion
The successful $15 million investment round positions Celltrio to significantly enhance its global presence and continue driving innovation in cell culturing and therapy automation. With the support of Premier Partners, Celltrio is set to scale its operations, broaden its market reach, and solidify its role as a leader in life sciences automation solutions.
Read the full article here:
venturebeat.com